# Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

> **NCT00541775** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 273 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Comparator: Rosiglitazone
- **DRUG:** Comparator: Placebo
- **DRUG:** Comparator: Metformin

## Key facts

- **NCT ID:** NCT00541775
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2015-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541775, "Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00541775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*